EGFR and neoplasm: Initial PET studies with fluorine-18-labeled reversible EGFR inhibitors in tumor-bearing animals demonstrated relatively low uptake or fast clearance of the reversible EGFRIs from the tumor area, at least in part due to active efflux from tumor cells (Mishani et al., 2008; Slobbe et al., 2012).